On the stock market since 2013, it operates in the world of health and science. It has 8 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $76K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 11 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $7.0M against $76K in annual sales.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 4 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, ARTH sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ARTH is a high-risk stock — not yet profitable, and its future rides on its product catching on.